RECRUITING

Human Blood Cell Disorders Tissue Bank

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.

Official Title

Human Blood Cell Disorders Tissue Bank

Quick Facts

Study Start:2009-04
Study Completion:2035-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00902447

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent.
  2. * Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care.
  3. * Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care.
  1. * Patients who are known to be anemic, with hemoglobin \<8.0g/dl.
  2. * Patients who are known to be infected with HIV.

Contacts and Locations

Study Contact

Yasmine Kieso, MSCR
CONTACT
ykieso@northwell.edu

Principal Investigator

Nicholas Chiorazzi, M.D.
PRINCIPAL_INVESTIGATOR
The Feinstein Institute for Medical Research

Study Locations (Sites)

The Feinstein Institute for Medical Research
Manhasset, New York, 11030
United States

Collaborators and Investigators

Sponsor: Northwell Health

  • Nicholas Chiorazzi, M.D., PRINCIPAL_INVESTIGATOR, The Feinstein Institute for Medical Research

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2009-04
Study Completion Date2035-01

Study Record Updates

Study Start Date2009-04
Study Completion Date2035-01

Terms related to this study

Keywords Provided by Researchers

  • Human Blood Cell Disorders
  • lymphoid, myeloid and erythroid proliferative disease

Additional Relevant MeSH Terms

  • Human Blood Cell Disorders
  • Lymphoid, Myeloid and Erythroid Proliferative Disease